Andrew Gillan of Janus Henderson Investors says he likes markets in the Philippines and Indonesia, and explains why it's difficult to invest in Vietnam despite its...Investingread more
China has other "weapons" in its trade battle with the United States — and selling off its U.S. Treasury holdings will not be one of them, said Richard McGregor, senior fellow...China Economyread more
Deutsche Bank Wealth Management's global chief investment officer predicted the Federal Reserve will cut interest rates twice in the next 12 months, but chances of a four-time...US Economyread more
Google's services have been blocked in China for several years, but the company still has businesses there, as the tech giant seeks to sell products to Chinese firms in...Technologyread more
Netflix can sustain its lofty valuation only if global subscriber growth can support increasing content spending and debt.Technologyread more
Germany online bank N26 said it raised a huge $170 million in additional funding, valuing the six-year-old fintech start-up at $3.5 billion.Technologyread more
Stocks in Asia traded lower on Thursday afternoon. Australia's jobs data showed the net number of jobs created was far below expectations.Asia Marketsread more
The House voted to table a resolution to start impeachment proceedings against President Donald Trump introduced by Rep. Al Green.Politicsread more
A photo editing app has introduced a few new wrinkles to the faces of celebrities — and to the ongoing discussion around personal digital security, NBC reports.Technologyread more
Property price gains across the wider U.K. have been slowing since 2016, according to the U.K.'s Office for National Statistics.Real Estateread more
The International Monetary Fund on Wednesday said that the U.S. dollar was overvalued by 6% to 12%, based on near-term economic fundamentals, while the euro, Japan's yen and...World Economyread more
* PBMs rise after White House kills rebate rule
* Biotechs, drugmakers drag on healthcare sector
* Fed's Powell resumes testimony before Congress
* Indexes: Dow up 0.7%, S&P 500 up 0.07%, Nasdaq down 0.2% (Updates to late afternoon)
NEW YORK, July 11 (Reuters) - The S&P 500 was little changed in afternoon trading on Thursday, with healthcare stocks mixed after the Trump administration withdrew a rule that would kill rebates.
Shares of pharmacy benefit managers gained as the news meant these companies would continue to benefit from after-market discounts from drugmakers. Health insurers and drug distributors also rose.
A 5.3% gain in UnitedHealth Group Inc helped the Dow break above 27,000 points for the first time. Cigna Corp surged 9%.
At the same time, drugmakers such as Merck & Co Inc and Pfizer Inc dropped and the Nasdaq biotech index fell 1.7%. The healthcare index was down 0.3%.
Helping to support stocks were comments from Federal Reserve Chairman Jerome Powell, which boosted expectations for an interest-rate cut.
Powell, in his first day of testimony before Congress on Wednesday, confirmed the U.S. economy was still under threat from disappointing factory activity, tame inflation and a simmering trade war and said the Fed stood ready to "act as appropriate." Powell testified before the Senate Banking Committee on Thursday.
The S&P 500 rose above the 3,000 level for the first time Wednesday following the news and hit a high of 3,002.33 on Thursday, but the index has been able to hold above that level.
"The fact that the market has tried several times this week to get through it and hold has been a big psychological negative," said Michael James, managing director of equity trading at Wedbush Securities in Los Angeles.
The Dow Jones Industrial Average rose 174.03 points, or 0.65%, to 27,034.23, the S&P 500 gained 1.97 points, or 0.07%, to 2,995.04 and the Nasdaq Composite dropped 13.86 points, or 0.17%, to 8,188.67.
Iron Mountain slumped after Bank of America Merrill Lynch downgraded the document storage company's shares to "underperform," citing recent declines in recycled paper pricing.
A Labor Department report showed U.S. underlying consumer prices rose by the most in nearly 1-1/2 years in June, but that was unlikely to change expectations the Fed would cut rates this month.
Declining issues outnumbered advancing ones on the NYSE by a 1.19-to-1 ratio. (Additional reporting by Medha Singh and Manas Mishra in Bengaluru; Editing by Shounak Dasgupta, Maju Samuel and Jonathan Oatis)